Outcomes with arsenic trioxide (ATO) in patients with newly diagnosed acute promyelocytic leukemia (APL).
| Reference . | N . | Induction Therapy . | Complete Remission (%) . | Molecular Remission (%)* . | Median Days to CR . | Post-remission Therapy . | OS (%) . | DFS (%) . | Median Follow-up (months) . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ATRA, all-trans retinoic acid; CT, chemotherapy; GO, gemtuzumab ozogamicin; CR, complete remission; DFS, disease-free survival; OS, overall survival; NA, not available | |||||||||
| * After induction or after consolidation | |||||||||
| ** Patients received CT if WBC > 10 × 109/L | |||||||||
| † Median reduction fold of PML/RARα after induction | |||||||||
| ‡ Low-dose chemotherapy (LDCT) | |||||||||
| § This study included 14 relapsed patients | |||||||||
| £6 = OS in patients with CR | |||||||||
| ¥ Seven patients received gemtuzumab ozogamicin if WBC > 10 × 109/L | |||||||||
| Lazo (2003) | 12 | ATO 0.15 mg/kg | 100 | 90 | 52 | ATO + CT (6 pts) or ATO (4 pts) or ATRA + CT (2 pts) | 80 (2y) | 80 (2y) | 24 |
| Shen (2004) | 20 | ATRA 25 mg/m2 (+ CT 11 pts)** | 95 | (7)† | 40 | CT × 3 → maintenance ATRA + LDCT‡ | NA | 68 (2y) | 18 |
| (Randomized) | 20 | ATO 0.16 mg/kg (+ CT 12 pts)** | 90 | (32† | 31 | CT × 3 → maintenance ATO + LDCT | NA | 85 (2y) | |
| 21 | ATO + ATRA (+ CT 14 pts)** | 95 | (119† | 25 | CT × 3 → maintenance ATRA + ATO + LDCT | NA | 100 (2y) | ||
| Jiung Hu (2005) | 56 | ATO 0.16 mg/kg + ATRA 25 mg/m2 | 92 | 93 | 26 | CT × 3 → ATO + ATRA + LDCT × 5 | 97 (3y) | 93 (3y) | 34 |
| Matthews (2005) | 72 | ATO 10 mg (+ CT 6 pts, + hydrea 37 pts) | 86 | 76 | 42 | ATO 28d × 1 → ATO 10d × 6 | 81 (2.5y) | 86 (2.5y) | 31 |
| Ghavamzadeh (2006) | 111§ | ATO 0.16 mg/kg | 86 | 92 | 30 | ATO 28d | 88 (3y)£ | 64 (2y) | 16 |
| Estey (2006) | 44 | ATO 0.15 mg/kg (+ GO 19 pts)¥ | 89 | 89 | 28 | ATO + ATRA × 4 (+ GO if Molecular Relapse or Persistence) | 86 (2y) | 86 (2y) | 16 |
| Reference . | N . | Induction Therapy . | Complete Remission (%) . | Molecular Remission (%)* . | Median Days to CR . | Post-remission Therapy . | OS (%) . | DFS (%) . | Median Follow-up (months) . |
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: ATRA, all-trans retinoic acid; CT, chemotherapy; GO, gemtuzumab ozogamicin; CR, complete remission; DFS, disease-free survival; OS, overall survival; NA, not available | |||||||||
| * After induction or after consolidation | |||||||||
| ** Patients received CT if WBC > 10 × 109/L | |||||||||
| † Median reduction fold of PML/RARα after induction | |||||||||
| ‡ Low-dose chemotherapy (LDCT) | |||||||||
| § This study included 14 relapsed patients | |||||||||
| £6 = OS in patients with CR | |||||||||
| ¥ Seven patients received gemtuzumab ozogamicin if WBC > 10 × 109/L | |||||||||
| Lazo (2003) | 12 | ATO 0.15 mg/kg | 100 | 90 | 52 | ATO + CT (6 pts) or ATO (4 pts) or ATRA + CT (2 pts) | 80 (2y) | 80 (2y) | 24 |
| Shen (2004) | 20 | ATRA 25 mg/m2 (+ CT 11 pts)** | 95 | (7)† | 40 | CT × 3 → maintenance ATRA + LDCT‡ | NA | 68 (2y) | 18 |
| (Randomized) | 20 | ATO 0.16 mg/kg (+ CT 12 pts)** | 90 | (32† | 31 | CT × 3 → maintenance ATO + LDCT | NA | 85 (2y) | |
| 21 | ATO + ATRA (+ CT 14 pts)** | 95 | (119† | 25 | CT × 3 → maintenance ATRA + ATO + LDCT | NA | 100 (2y) | ||
| Jiung Hu (2005) | 56 | ATO 0.16 mg/kg + ATRA 25 mg/m2 | 92 | 93 | 26 | CT × 3 → ATO + ATRA + LDCT × 5 | 97 (3y) | 93 (3y) | 34 |
| Matthews (2005) | 72 | ATO 10 mg (+ CT 6 pts, + hydrea 37 pts) | 86 | 76 | 42 | ATO 28d × 1 → ATO 10d × 6 | 81 (2.5y) | 86 (2.5y) | 31 |
| Ghavamzadeh (2006) | 111§ | ATO 0.16 mg/kg | 86 | 92 | 30 | ATO 28d | 88 (3y)£ | 64 (2y) | 16 |
| Estey (2006) | 44 | ATO 0.15 mg/kg (+ GO 19 pts)¥ | 89 | 89 | 28 | ATO + ATRA × 4 (+ GO if Molecular Relapse or Persistence) | 86 (2y) | 86 (2y) | 16 |